Smith & Nephew (FTSE:SN, NYSE:SNN) completed the acquisition of substantially all the assets of Healthpoint Biotherapeutics, paying $782 million in cash financed by the company’s existing cash resources and bank facilities.
Healthpoint Biotherapeutics
Smith & Nephew’s $782M Healthpoint buyout raises eyebrows
Healthcare giant Smith & Nephew (FTSE:SN, NYSE:SNN) today announced a $782 million cash bid to acquire wound care products maker Healthpoint Biotherapeutics, a move that sparked mixed reactions from Wall Street.